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Secondary glaucoma due to ocular and orbital tumors can be a diagnostic 
challenge. It is an essential differential to consider in eyes with a known tumor as 
well as with unilateral, atypical, asymmetrical, or refractory glaucoma. Various 
intraocular neoplasms including iris and ciliary body tumors (melanoma, metasta-
sis, lymphoma), choroidal tumors (melanoma, metastasis), vitreo-retinal tumors 
(retinoblastoma, medulloepithelioma, vitreoretinal lymphoma) and orbital tumors 
(extra-scleral extension of choroidal melanoma or retinoblastoma, primary orbital 
tumors) etc. can lead to raised intraocular pressure. The mechanisms for glaucoma 
include direct (tumor invasion or infiltration related outflow obstruction, tra-
becular meshwork seeding) or indirect (angle closure from neovascularization or 
anterior displacement or compression of iris) or elevated episcleral venous pressure 
secondary to orbital tumors. These forms of glaucoma need unique diagnostic 
techniques and customized treatment considerations as they often pose therapeutic 
dilemmas. This chapter will review and discuss the mechanisms, clinical presenta-
tions and management of glaucoma related to ocular and orbital tumors.
Keywords: ocular tumors, secondary glaucoma, orbital tumors, angle infiltration, 
neovascular glaucoma, neoplastic glaucoma
1. Introduction
With the advent of constantly evolving and advancing ophthalmic imaging tech-
niques as well as surgical modalities in the field of ophthalmic diseases, diagnostic 
accuracy, and treatment outcomes of ocular as well as orbital tumors have improved 
remarkably over the past few years. Raised intraocular pressure (IOP) is known to 
be one of the presenting features or associated finding for numerous ocular as well 
as orbital tumors. Ocular and orbital tumors can cause secondary glaucoma due to 
various mechanisms. They often pose a diagnostic challenge as well as a therapeutic 
dilemma owing to the complex pathophysiology involved. A thorough clinical 
evaluation, appropriate index of suspicion and optimum use of ancillary testing can 
lead to a proper diagnosis and management in such scenario.
Intraocular tumors that can lead to secondary glaucoma are malignancies like 
iris melanoma, iris metastasis, iris lymphoma, ciliochoroidal melanoma, retino-
blastoma as well as benign pathologies like iris melanocytoma, benign ciliary body 
medulloepithelioma, diffuse choroidal hemangioma. [1] Indicators for a possible 
underlying intraocular tumor are, markedly elevated and often asymmetric level of 
IOP, acquired iris heterochromia, glaucoma non-responsive to optimum treatment 
or accompanying distinctive ocular features. [1, 2] The mechanism by which these 
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tumors can cause secondary glaucoma varies with tumor type, size, and extent of 
the main tumor as well as seeding, tumor location, growth pattern, ongoing treat-
ment along with secondary features related to the tumor. [3] Iris and predominantly 
ciliary body tumors located in anterior segment can cause glaucoma by direct 
infiltration of anterior chamber angle or because of iris neovascularization; while 
large tumors originating in retina or choroid are likely to cause glaucoma follow-
ing iris neovascularization because of long standing or total retinal detachment or 
secondary angle closure. [1, 2]
Orbital tumors which can be congenital, traumatic, inflammatory, vascular, or 
neoplastic in origin may cause secondary glaucoma due to mass effect or anatomical 
and vascular changes leading to raised IOP [4] Orbital tumors causing raised orbital 
pressure may directly increase the IOP by increasing hydrostatic pressure around 
the globe or indirectly by raising the episcleral venous pressure.
Management of secondary glaucoma due to ocular and orbital tumors depends 
on both tumor characteristics and glaucoma related factors. Treatment of primary 
tumor may lead to IOP control in some cases while for others, management options 
include medical management, laser trabeculoplasty, transscleral cyclophotocoagu-
lation, anti-VEGF injections, minimally invasive glaucoma surgery (MIGS), filter-
ing or shunting surgery or enucleation. Glaucoma surgery like filtering or shunting 
procedure can be performed with due caution in proven benign or completely 
regressed tumors post-treatment. Such surgeries in an eye with suspected but 
unproven benign/malignant ocular tumor must be avoided to prevent unintended 
iatrogenic tumor dispersion or seeding especially in cases with iridociliary tumors 
or retinoblastoma.
2. Mechanisms of glaucoma secondary to ocular and orbital tumors
A. Direct mechanism-
a. Solid tumor invasion- related outflow obstruction
b. Infiltrative tumor -related outflow obstruction
c. Trabecular meshwork seeding
B. Indirect mechanism-
a. Angle closure from neovascularization
b. Angle closure (compressive and rotational)
c. Ghost cell- Hemolytic
d. Elevated episcleral venous pressure
3. Ocular tumor related glaucoma
3.1 Anterior segment tumors
Anterior uveal tumors known to cause secondary glaucoma are iris/ciliary 
body melanocytoma, iris melanoma (nodular or diffuse), ciliary body melanoma 
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(nodular or ring melanoma), iris lymphoma and iris metastasis. Direct invasion 
of the anterior chamber angle by infiltration followed by neovascularization and 
trabecular meshwork tumor seeding are the common etiologies of raised IOP in iris 
tumors; while pigment dispersion followed by direct angle invasion are the common 
etiologies for same in pigmented ciliary body tumors. [1, 2, 5, 6]
Iris melanocytoma, a variant of melanocytic iris nevus is a deeply pigmented 
benign tumor which is well circumscribed, often dark brown to black dome shaped 
lesion with cobblestone surface and feathery edges showing echogenic nodular 
thickening of iris on ultrasound biomicroscopy (UBM). (Figure 1A–C) [2, 7] 
Melanocytoma can undergo spontaneous necrosis with pigment dispersion leading 
to pigment-laden melanophages seeding the angle causing secondary glaucoma. [8] 
(Figure 1D) Secondary glaucoma has been reported in 11% of cases in a series of 
47 iris melanocytoma where pigmented keratic precipitates and anterior chamber 
inflammation were identified as factors predictive of development of raised IOP 
emphasizing the role of macrophages in the anterior chamber angle. [7]
Suspected melanocytoma can be observed cautiously. They are very rarely 
known to show malignant transformation. [9] Clear corneal approach fine needle 
aspiration biopsy, minimally invasive Finger Iridectomy technique (FIT), iridec-
tomy or iridogoniocyclectomy can be utilized to obtain histopathological diagnosis 
in atypical iris nevi and suspected melanocytoma. [7, 10] Secondary glaucoma 
demonstrating melanocytoma eyes can be treated medically, by transscleral photo-
coagulation, by sector iridectomy or with glaucoma filtration surgery. [7, 8, 11, 12] 
However, a diagnostic confirmation of the lesion by prior biopsy and histopathology 
Figure 1. 
(A) Slit lamp image of iris melanocytoma; (B) Gonioscopy image of iris melanocytoma with extension of 
pigmentation up to the angle, (C) ultrasound biomicroscopy (UBM) image of iris melanocytoma appearing as 
irregular hyperreflective lesion on iris surface; (D) large iris melanocytoma leading to raised IOP due to angle 
closure glaucoma (compressive angle closure) {image credit for Figure 1A–C Dr. Paul T Finger MD, FACS, 
Director, The New York Eye Cancer Center, New York USA}.
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is mandated before planning a filtering surgery. Local surgical resection can be 
used to treat the secondary glaucoma caused by necrotic iris melanocytoma. [8, 13] 
Enucleation is reserved for painful blind eyes or eyes with absolute glaucoma.
Iris and iridociliary melanoma are the least common variant of uveal melanoma 
constituting only 2–3% of cases and have documented metastatic rate of 10.7–11%. 
[14–16]. Iris melanoma presents as a variably pigmented lesion (melanotic or 
amelanotic) which can be well circumscribed- nodular type, flat pigmented on 
iris surface- diffuse type and rarer predominantly trabecular meshwork involving 
type. (Figure 2) Secondary glaucoma has been reported in 33% of cases with iris 
melanoma while, with 100% of those with trabecular meshwork melanoma. [6, 17] 
Mechanisms include direct angle invasion (infiltration), iris neovascularization and 
trabecular meshwork seeding (melanomalytic glaucoma). [2, 3, 6] Unilateral find-
ings of markedly elevated IOP, heterochromia iridis along with pigment dispersion 
onto the corneal endothelium, anterior iris surface and into the angle point towards 
melanomalytic glaucoma. [2, 18] Diffuse iris melanoma should be suspected in all 
cases of iris heterochromia and unilateral glaucoma. (Figure 2B and D) [2, 19]  
Morphological features of iris melanoma such as diffuse tumor location (>1 quad-
rant), posterior tumor margin involving the angle, reduced median tumor thickness 
(flat configuration) and greater extent of tumor seeding on the iris stroma and angle 
have been statistically related to presence of glaucoma at presentation. [6] Patients 
with iris melanoma and secondary glaucoma are at significantly higher risk of 
systemic metastasis with a hazard ratio of 4.51 compared to iris melanoma without 
Figure 2. 
(A) Slit lamp image of iris melanoma showing correctopia, ectropion uveae and extension up to the angle, (B) 
slit lamp image of diffuse iris melanoma presenting with angle closure, (C) slit lamp image of ciliary body 
melanoma with iris infiltration presenting as secondary glaucoma with hyphema. (D) Gonioscopy image of 
blood vessel (black arrowhead) at the anterior chamber angle in a case of diffuse iris melanoma with angle 
closure depicted in Figure 2B. {image credit for Figure 1 A, B, D- Dr. Paul T Finger MD, FACS, Director, The 
New York Eye Cancer Center, New York USA and for Figure 2C- Dr. Santosh G Honavar MD FACS, Director, 
Ocular Oncology Services, Centre For Sight Hospital, Hyderabad, India}.
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glaucoma. [3, 6] Possible explanation being-tumor location and its discohesive 
nature along with raised IOP that enables the egress of tumor cells into emissary 
veins leading to distant metastasis. [2, 6, 20].
Management of iris and iridociliary melanoma depends upon tumor size, 
location or extent, tumor seeding and presence of tumor related glaucoma. [15, 
20] Local resection (iridectomy, iridocyclectomy), plaque brachytherapy, proton 
beam radiotherapy and enucleation are available treatment options for both 
nodular as well as diffuse iris melanoma. [6, 15, 20, 21] Secondary glaucoma 
in association with iris melanoma can be managed with medications, trans-
scleral photocoagulation or laser trabeculoplasty. [22] Antivascular endothelial 
growth factor (anti-VEGF) injections can be tried in neovascular glaucoma. 
[23] Cases with refractory glaucoma resulting in blind painful eyes may warrant 
enucleation. [24] Filtering, shunting surgery or MIGS should be avoided in eyes 
with untreated tumor to prevent tumor spread outside of the globe. Diffuse iris 
melanoma or trabecular meshwork melanoma if misdiagnosed or missed prior to 
performing above named procedures can warrant enucleation for further tumor 
control. [3, 19]
Ring melanoma of the iris and ciliary body are a rare entity constituting only 
0.3% of all uveal melanomas while having a poor prognosis owing to metastatic 
rate of up to 50%. [25]. The later could be likely due to delayed diagnosis as ring 
melanoma tend to grow circumferentially involving iris and entire ciliary body 
making them less obvious on ophthalmic examination. Prominent episcleral 
(sentinel) vessels, anterior chamber shallowing, multinodular tumor configura-
tion, unilateral lens changes and occasional extra-scleral extension, light blockage 
on transillumination and ultrasonographic hollowness with intrinsic vascular 
pulsations are salient diagnostic features suggestive of ring melanoma. [25, 26] 
They tend to initially manifest with low intraocular pressure and later develop 
secondary glaucoma and secondary retinal detachment. Secondary glaucoma has 
been reported in 35% of cases. [25] The mechanisms involved are direct angle 
infiltration, trabecular meshwork seeding, angle closure and neovascularization 
of iris. [2, 3, 27–29] Plaque radiotherapy, proton beam radiotherapy or enucleation 
are available management options for the tumor. [25, 26, 30] Medical management, 
transscleral cyclophotocoagulation to uninvolved ciliary body or laser trabecu-
loplasty to uninvolved angle can be tried to control glaucoma in salvaged eyes. 
However, refractory cases require enucleation. [3] High index of suspicion is war-
ranted when examining a case of unilateral refractory glaucoma with multinodular 
thickening of angle structures to avoid misdiagnosis as uveal effusion. Ultrasound 
biomicroscopy in such a case can help in identifying the tumor. Hurried shunting 
or filtering surgery for IOP control in tumor containing eyes can lead to tumor 
spread and further necessitate enucleation. [29, 31]
Iris and ciliary body metastasis constitute 8% and 2% of all cases of uveal 
metastasis respectively with breast and lung cancers being the most common 
primary tumors. [32] They tend to appear as solitary or multiple yellow, white, or 
pink stromal nodules with hyphema or pseudo hypopyon. They may present as 
ill-defined iris or ciliary body thickening in a setting of iridocyclitis. Ultrasound 
biomicroscopy (UBM) is useful in suspicious cases. (Figure 3A and B) Secondary 
glaucoma has been reported in about 37% of iris metastasis with angle invasion and 
iris neovascularization as mechanisms for raised IOP. [33] Treatment of primary, 
plaque brachytherapy, external beam radiotherapy (EBRT) or systemic chemother-
apy are management options for iris and ciliary body metastasis. [2, 3, 33] Medical 
management, transscleral laser photocoagulation or laser trabeculoplasty can be 




Iris lymphoma, localized or diffuse is a differential diagnosis of iris melanoma 
or metastasis. Unilateral or bilateral presentation of diffuse non-granulomatous 
uveitis with raised IOP in open angles, uveitis- glaucoma- hyphema syndrome 
(UGH) or steroid resistant pseudo-uveitis are documented clinical manifestations 
of intraocular lymphoma. [36–38] The mechanism for raised IOP include angle 
infiltration, angle closure, hyphema. [3, 37] Plaque radiotherapy, EBRT, systemic 
chemotherapy have been used for management of iris lymphoma while, the raised 
IOP may respond to medical therapy, transscleral cyclophotocoagulation or laser 
trabeculoplasty. Enucleation is reserved for refractory cases. [2, 3]
Leukemic infiltration from acute lymphocytic leukemia (ALL) and acute 
myeloid leukemia (AML) in the anterior chamber, trabecular meshwork and 
Schlemm’s canal can cause outflow obstruction and raised IOP. [2] ALL is the 
most common cause of both intraocular leukemia and secondary leukemia 
related glaucoma. Leukemia with central nervous system (CNS) involvement 
has been strongly associated with leukemic hypopyon and glaucoma. [2, 39] 
Treatment with systemic chemotherapy or EBRT is recommended for these. 
EBRT is known to show rapid resolution of angle infiltration in cases with 
secondary glaucoma. [2]
Other disorders like: Multiple myeloma, a malignant proliferation of plasma 
cells characterized by monoclonal production od immunoglobulins; Juvenile 
Xanthogranuloma, a benign histiocytic skin disorder can also affect anterior seg-
ment and lead to raised IOP. [2]
Figure 3. 
(A) Slit lamp image of iris and ciliary body metastasis from lung adenocarcinoma showing correctopia, 
ectropion uveae, neovascularization of iris presenting with raised IOP (B) Ultrasound biomicroscopy image 
of iris metastasis with blunting of anterior chamber angle and thickened ciliary body (C) Slit lamp image of 
large choroidal melanoma presenting with intratumoral hemorrhage and raised IOP. (D) Ultrasound B scan 
of lesion in (C) showing low to moderately reflective choroidal melanoma with surrounding detached retina 
{image credit for Figure 1 A, B- Dr. Paul T Finger MD, FACS, Director, The New York Eye Cancer Center, 
New York USA}.
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3.2 Posterior segment tumors
3.2.1 Choroidal tumors
Choroidal melanoma is the most common primary intraocular malignancy 
found in adults and the most common uveal melanoma encountered overall. 
Clinically it manifests as a dome shaped or mushroom shaped pigmented (mela-
notic) or non-pigmented (amelanotic) choroidal mass often associated with 
surrounding sub-retinal fluid, overlying orange pigmentation and exudative 
retinal detachment. (Figure 3C) The ultrasound B scan shows low to moderately 
reflective choroidal lesion with associated detached retina or occasional vitreous 
hemorrhage. (Figure 3D) Compared to anterior uveal melanomas, choroidal 
melanoma is less likely to cause secondary glaucoma (2%). [2, 3] Secondary 
glaucoma has been reported in both known and previously undiagnosed cases 
of choroidal melanoma. [2, 3] Secondary glaucoma has also been termed as the 
‘masquerading sign’ for uveal melanomas in the literature. [40, 41] The reported 
mechanisms for raised IOP include iris neovascularization, direct angle invasion, 
angle closure, hyphema and suprachoroidal hemorrhage. [1, 3] Globe sparing epi-
scleral plaque brachytherapy is commonly used modality of treatment followed by 
proton beam radiotherapy and local resection. Enucleation is warranted for large 
melanomas not amenable to radiotherapy or those causing absolute glaucoma. 
For control of IOP, medical management, transscleral cyclophotocoagulation or 
laser trabeculoplasty can be tried. In contrast to anterior uveal melanomas, for 
choroidal melanoma not involving ciliary body or iris root MIGS, filtering and 
shunting surgery can be considered in eyes where complete tumor regression has 
been achieved. [3]
Contrary to traditional thinking, a recent study of analysis of glaucoma drain-
age device surgery for control of IOP in treated (totally regressed) uveal melanoma 
(both anterior as well as posterior) did not find a greater risk of local or extraocular 
recurrence after a median follow up of 2 years. [42] However, further analysis with 
larger sample size and longer follow up duration is warranted, and caution needs to be 
 exercised while deciding regarding treatment options for control of IOP in such cases.
Choroidal metastasis represents around 90% of total uveal metastasis. Breast, 
lung, kidney, gastrointestinal tract, and cutaneous melanoma are the leading sites 
of primary malignancies. [32] (Figure 4A) Secondary glaucoma has been reported 
in 1% of cases with mechanism being angle closure and iris neovascularization. [24] 
Plaque brachytherapy, photodynamic therapy, EBRT, systemic chemotherapy or 
enucleation are available management options for choroidal metastasis. Secondary 
glaucoma can be managed like choroidal melanoma related secondary glaucoma 
described above.
Choroidal hemangioma is a benign vascular hamartoma presenting as an 
orange- red mass showing hyperreflectivity on ultrasound B scan. It can be solitary 
or ‘circumscribed’ or ‘diffuse’. (Figure 4C) Circumscribed tumors cause secondary 
glaucoma in 1% of cases of due to angle closure and iris neovascularization due to 
total retinal detachment. [43] Diffuse choroidal hemangiomas appear as diffuse 
choroidal thickening and have been said to give ‘tomato-catsup’ fundus impression. 
They are known to be associated with Sturge–Weber syndrome (SWS). The raised 
IOP found in SWS has been found to be due to developmental anomalies of anterior 
chamber and raised episcleral venous pressure and often unrelated to diffuse cho-
roidal hemangioma. Total retinal detachment and iris neovascularization can rarely 
cause secondary glaucoma in such eyes. [3] Management options include plaque 
brachytherapy (for circumscribed as well as to the nodular component if any, in the 
diffuse variant), photodynamic therapy or EBRT to halt tumor growth and control 
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of subretinal fluid to achieve stabilization of visual acuity. [44, 45] For control of 
IOP, medical management, transscleral cyclophotocoagulation, laser trabeculo-
plasty, MIGS, filtering or shunting surgeries can be performed.
3.2.2 Retinal tumors
Retinoblastoma is the most common primary intraocular malignancy found in 
pediatric population with estimated incidence of 1:16,000–18,000 live births. [46] 
White reflex or ‘leukocoria’ is the most common presenting feature of retinoblas-
toma. Presence of an intraocular mass with presence of intratumoral calcifications 
demonstrated on ultrasound B scan and/or computed tomography (CT) scan is 
pathognomic of the malignancy. Retinoblastoma can show endophytic, exophytic, 
diffuse or mixed growth pattern with presence of vitreous seeds. Secondary 
glaucoma is reported in 17% of cases due to iris neovascularization (5%), angle 
closure (1%), anterior tumor seeding (<1%) or related to hyphema (<1%). [24] 
Retinoblastoma is an important differential diagnosis to be considered in any 
pediatric uveitis or glaucoma. Delayed presentation and often misdiagnosis as either 
only intraocular inflammation or glaucoma can result in delay in retinoblastoma 
treatment and greater risk of metastasis with poor prognosis. [1, 2] Neovascular 
glaucoma is the most common cause of retinoblastoma related raised IOP which is 
postulated to be mediated by vascular endothelial growth factor (VEGF) produced 
by necrotic and hypoxic tumor cells. [47] (Figure 5A and B) Other causes include 
pupillary block and tumor seeding in anterior chamber angle. Glaucoma in retino-
blastoma has been reported to be associated with metastasis related to optic nerve 
invasion by tumor cells. [48] Presence of secondary glaucoma at presentation has 
Figure 4. 
(A) Montage fundus image of choroidal metastasis from breast carcinoma presenting with multifocal lesions, 
retinal detachment and raised IOP. (B) Posterior pole fundus image of the same patient (A) showing radiation 
retinopathy after stereotactic radiotherapy (45Gy) (C) Fundus picture showing circumscribed choroidal 
hemangioma.
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also been identified as a predictor for high-risk histopathological features of retino-
blastoma along with prolonged duration of symptoms. [49] Management options 
for retinoblastoma depend upon age at presentation, laterality as well as grouping 
and staging of the disease. Modalities used are systemic chemotherapy, intra-arterial 
chemotherapy, intravitreal chemotherapy, focal lasers, cryotherapy, plaque radio-
therapy and Orbital radiotherapy. Non-salvageable and advanced tumor containing 
eyes need enucleation. The IOP can get controlled as tumor regression is achieved in 
some eyes precluding any need of separate management for the glaucoma. Medical 
management, laser trabeculoplasty or cyclophotocoagulation can be tried in selected 
eyes post-tumor treatment. Any filtering surgeries, shunting procedures, MIGS 
should be avoided in tumor containing eyes to avoid extra-scleral extension of tumor.
4. Glaucoma associated with management of ocular tumors
Radiotherapy associated glaucoma- Radiotherapy is increasingly being used for 
management of intraocular tumors as means of eye and vision salvage. The modali-
ties in practice are plaque brachytherapy (Iodine125, Palladium103, Ruthenium106), 
proton beam radiotherapy, stereotactic radiotherapy, and external beam radiother-
apy. Glaucoma has been reported as one of the common side effects of radiation. The 
common cause of radiation induced raised IOP is development of iris neovascular-
ization and subsequent neovascular glaucoma (NVG). Pathogenesis of iris neovascu-
larization is multifactorial, including increased release angiogenic factors, anterior 
and posterior segment ischemia, vascular occlusion, tumor hypoxia, radiation 
retinopathy (Figure 4D) and optic neuropathy. [50] Secondary open angle glaucoma 
Figure 5. 
(A) Group E retinoblastoma presenting with total retinal detachment, iris neovascularization and neovascular 
glaucoma (clinical risk factors) (B) iris neovascularization (black arrowhead) (C) post chemotherapy tumor 
necrosis induced vitreous hemorrhage and secondary glaucoma in an eye with retinoblastoma (D) secondary 
glaucoma and sterile orbital inflammation in a case of retinoblastoma on systemic chemotherapy.
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has also been noted in radiotherapy treated tumor eyes apart from NVG. After Iodine 
125 plaque brachytherapy for uveal melanoma reported Kaplan–Meier estimated risk 
of secondary open angle glaucoma was 15% at 5 years with higher incidence in earlier 
postoperative period, whereas estimated incidence of NVG was 13% at 5 years. [51] 
The risk factors for development of radiation induced secondary glaucoma (both 
open angle and NVG) include larger tumor size, higher radiation dose, involvement 
of iris and ciliary body and presence of retinal detachment. [2, 51–53] Proton beam 
radiotherapy for uveal melanoma has reported NVG rate of 12–31% at 5 years with 
greater tumor height, older age at presentation and larger tumor diameter as identi-
fied risk factors. [54] Anti- VEGF injections as well as pan-retinal photocoagulation 
for treatment of ocular ischemia or radiation retinopathy might be useful to reduce 
rate of neovascular glaucoma induced by radiation retinopathy.
Tumor necrosis induced glaucoma- Hemolytic glaucoma (Ghost cell glau-
coma) is known to occur in tumor containing eyes with vitreous hemorrhage 
following systemic chemotherapy or focal tumor treatments. It occurs due to 
obstruction of trabecular meshwork by red blood cells, their debris and macro-
phages filled with hemorrhagic components from phagocytosis of vitreous hemor-
rhage. It can be observed in retinoblastoma eyes showing tumor necrosis as well as 
vitreous hemorrhage post chemotherapy. (Figure 5C and D).
4.1 Special considerations
In instances where patient seeks attention with glaucoma as the presenting 
feature, a detailed work up involving slit lamp examination, dilated fundus examina-
tion, gonioscopy of anterior chamber angle, high frequency ultrasound microscopy 
(UBM) and ultrasound B scan of posterior segment will provide essential clues about 
diagnosis of possible intraocular tumor. Initial management with IOP lowering medi-
cations should be the first line treatment with simultaneous investigation for under-
lying cause. [2] When the tumor presents with atypical features or causes diagnostic 
uncertainty, a diagnostic biopsy is warranted in managing such case of secondary 
glaucoma. [55] Systemic work up with the help of positron emission tomography 
(PET) CT scan can come in handy while evaluating a case of possible secondary 
ocular metastasis by highlighting an existing primary malignancy elsewhere.
4.2 Orbital tumor related glaucoma
The orbit is a pyramidal structure limited by bony walls except from anteriorly 
where it is limited by soft tissue i.e., orbital septum and eyelids. Thus, any instances 
of increased orbital volume may lead to increased hydrostatic pressure in the orbit. 
This increased orbital pressure can have a direct effect of IOP by raised hydrostatic 
pressure around the eye or indirect effect by compression of episcleral and orbital 
veins raising venous pressure. The episcleral venous system mainly empties into the 
anterior ciliary and superior ophthalmic veins and eventually draining into cavern-
ous sinus. Thus, any disease process that might affect this drainage pathway due 
to structural, occlusive, compressive, or destructive pathophysiology can alter and 
raise IOP causing secondary glaucoma. [4] Focal mass effect due to tumors or swol-
len extraocular muscles may directly compress the eye globe leading to raised IOP 
while, vascular changes affecting venous pressure due to compression of episcleral 
veins or altered arterio-venous flow may also increase IOP indirectly.
Table 1 summarizes the broad etiological classes of orbital tumors leading to rise 
in IOP and secondary glaucoma. Open angle glaucoma is more common in the listed 
diseases however, angle closure along with acute angle closure glaucoma has also 
been reported in variety of pathologies.
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IOP evaluation should be routinely performed when evaluating a case of 
suspected orbital tumor or pathology. Gonioscopic examination can provide 
essential information regarding the status of the anterior chamber angle as well 
as show evidence of blood in Schlemm’s canal as the distinguishing feature of 
elevated venous pressure. The treatment of primary orbital pathology along 
with medical management of raised IOP is indicated for control of orbital tumor 
related secondary glaucoma.
In sum, glaucoma can be associated with various ocular as well as orbital tumors. 
It may constitute one of the many manifesting clinical features or be the sole pre-
senting feature of these pathologies. Appropriate diagnosis and timely management 
of these tumors can help eye and vision salvage; however, a misdiagnosis or delayed 
diagnosis due to initial presentation as secondary glaucoma can lead to catastrophic 
sequel necessitating enucleation and can pose a greater risk to life. A thorough clini-
cal evaluation, use of ancillary testing and stepwise management can help achieve 
optimum visual outcome and overall survival in cases with ocular or orbital tumors.
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Sr. No Etiology Example
1 Inflammatory Non-specific Orbital Inflammatory Disease (NSOID)
Thyroid eye disease
Orbital granulomatous disease
Orbital Foreign Body granuloma
Juvenile Xanthogranuloma (orbital histiocytosis)












4 Secondary Orbital metastasis (from breast, lung carcinoma)
Orbital chloroma (Acute myeloid leukemia)
Multiple myeloma
Invasive (secondary) ocular melanoma
Extra-scleral (orbital) extension of retinoblastoma
Invasive (secondary) squamous cell carcinoma
5 Miscellaneous Orbital amyloidosis
Mucopolysaccharidoses
Phakomatosis (Neurocutaneous syndromes)
Collagen tissue disorders (Lupus erythematosus, Wegener granulomatosis)
Table 1. 
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